AVT03 Biosimilar Approved: A Strategic Analysis
The European Commission has officially approved AVT03, a biosimilar version of the medications Prolia and Xgeva. These drugs are vital for treating bone loss and preventing complications in patients with osteoporosis, cancer, and other conditions. This approval marks a significant step for Dr. Reddy’s Laboratories and their partners, opening access to a more affordable treatment option.
Key Points
- AVT03 approved across all EU nations, including EEA countries.
- Biosimilar offers a cost-effective alternative to Prolia & Xgeva.
- Approval based on strong clinical and analytical evidence.
- Dr. Reddy’s holds exclusive U.S. rights for ACVybra & Xbonzy.
- Alvotech handles development and manufacturing of AVT03.
- Strategic partnership aims to expand patient access to essential medicines.
Prolia and Xgeva are used to treat bone loss in women and men, and to prevent bone problems in cancer patients. They work by slowing down the breakdown of bone tissue. The European Commission’s approval means that AVT03 can now be used in all countries within the European Union and the European Economic Area.
The decision followed a positive assessment from the Committee for Medicinal Products for Human Use (CHMP) in September 2025. This review considered detailed comparisons of AVT03 with the original drugs, how the body processes the medications, and the results of a special clinical trial. The biosimilar will be sold under the names Acvybra and Xbonzy.
Dr. Reddy’s has partnered with Alvotech for the development and production of AVT03. Dr. Reddy’s will handle getting the drug approved and selling it in the United States and Europe. They will be selling Acvybra (60mg/mL) in a pre-filled syringe and Xbonzy (70mg/mL) in a vial.
Access to affordable biosimilars is critical for improving patient outcomes and managing healthcare costs.
